A study of 237 neuroblastoma specimens revealed that 48.4% of samples possessed single-nucleotide variants (SNVs) and/or copy number alterations in DDR-associated genes located in 11q, suggesting that PARP inhibitors could be indicated in these patients [67]. The gene discussed is PARP1; the disease is neuroblastoma.